Status:
WITHDRAWN
Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke
Lead Sponsor:
Xuanwu Hospital, Beijing
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in comb...
Eligibility Criteria
Inclusion
- 18-80 years old 2. NIHSS score\>6 3. For the first stroke, MRI showed anterior circulation infarction 4. Patients who meet the mechanical thrombectomy treatment by MRI assessment within 24 hours
Exclusion
- Patients receiving Alteplase thrombolysis
- Other diseases of the central nervous system
- There has been a neurological disability in the past (mRS score\>2)
- Difficulty swallowing
- Arrhythmia, atrioventricular block
- Use of anti-tumor drugs, other immunosuppressive and immunomodulatory drugs
- Macular edema
- Magnetic resonance angiography shows vertebra-basilar artery obstruction
- Hemorrhagic stroke
- Patients who are known to have hypersensitivity to dimethyl fumarate or any excipients of this product
- Pregnant and lactating women
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04891497
Start Date
June 1 2021
End Date
December 31 2021
Last Update
October 25 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.